AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 525146: Decapropylene glycol, monoallyl ether, acetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-prop-2-enoxypropoxy)propoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propyl acetate. Molecular Formula: C35H68O12. Molecular Weight: 680.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526020: p-Synephrine, DTFMB-TMS

Chemical compound data from PubChem database. IUPAC Name: N-methyl-3,5-bis(trifluoromethyl)-N-[2-trimethylsilyloxy-2-(4-trimethylsilyloxyphenyl)ethyl]benzamide. Molecular Formula: C24H31F6NO3Si2. Molecular Weight: 551.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
SHIP Emergency Department Visit Rate Due To Asthma 2008-2017

Emergency Department Visit Rate Due To Asthma - This indicator shows the rate of emergency department visits due to asthma per 10,000 population. Asthma is a chronic health condition which causes very serious breathing problems. When properly controlled through close outpatient medical supervision, individuals and families can manage their asthma without costly emergency intervention. In Maryland, there are nearly 50,000 emergency department visit related to asthma each year.
Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons

Background
          BMP-5 is expressed in the nervous system throughout development and into adulthood. However its effects on neural tissues are not well defined. BMP-5 is a member of the 60A subgroup of BMPs, other members of which have been shown to stimulate dendritic growth in central and peripheral neurons. We therefore examined the possibility that BMP-5 similarly enhances dendritic growth in cultured sympathetic neurons.
        
        
          Results
          Sympathetic neurons cultured in the absence of serum or glial cells do not form dendrites; however, addition of BMP-5 causes these neurons to extend multiple dendritic processes, which is preceded by an increase in phosphorylation of the Smad-1 transcription factor. The dendrite-promoting activity of BMP-5 is significantly inhibited by the BMP antagonists noggin and follistatin and by a BMPR-IA-Fc chimeric protein. RT-PCR and immunocytochemical analyses indicate that BMP-5 mRNA and protein are expressed in the superior cervical ganglia (SCG) during times of initial growth and rapid expansion of the dendritic arbor.
        
        
          Conclusions
          These data suggest a role for BMP-5 in regulating dendritic growth in sympathetic neurons. The signaling pathway that mediates the dendrite-promoting activity of BMP-5 may involve binding to BMPR-IA and activation of Smad-1, and relative levels of BMP antagonists such as noggin and follistatin may modulate BMP-5 signaling. Since BMP-5 is expressed at relatively high levels not only in the developing but also the adult nervous system, these findings suggest the possibility that BMP-5 regulates dendritic morphology not only in the developing, but also the adult nervous system.
Ohio (OH)

This report presents Ohio\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Ohio for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 527050: 2,6-Dimethyl-3,7-octadiene-2,6-diol

Chemical compound data from PubChem database. IUPAC Name: 2,6-dimethylocta-3,7-diene-2,6-diol. Molecular Formula: C10H18O2. Molecular Weight: 170.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400044-T1: [Translated] VENDING MACHINE FOR PACKAGED PRODUCTS

Packaged food-product vending machine comprising an outer casing containing said packaged products, a product delivery compartment formed of an openable lid installed on the front wall of the outer casing, a rear wall delimiting said delivery compartment on the rear side thereof, a front wall delimiting said delimiting compartment on the front side thereof and adapted to be rotated from a closing position, in which it lies flush with the front wall of the outer casing, to an opening position, in which it protrudes therefrom. The delivery compartment is provided with a substantially planar, thin and flexible member that is applied with an inner edge thereof on to the rear wall of the compartment and, with an opposite edge thereof, on to the inner face of the related front wall.
Patent AT-E261765-T1: [Translated] DEVICE AND METHOD FOR SYNTHESIS OF POLYMERS USING ARRAYS

The present invention provides a polymer synthesis apparatus for building a polymer chain by sequentially adding polymer units in a reagent solution, said apparatus comprising:   a head assembly having a plurality of nozzles mounted thereto in generally spaced-apart relation, each nozzle being coupled to a reservoir of liquid reagent for controlled delivery therethrough; a base assembly having at least one reaction well; a transport mechanism coupled to at least one of said head assembly and said base assembly to produce relative movement therebetween to position said reaction well and a selected one nozzle in alignment for deposition of a liquid reagent into said reaction well for synthesis of a polymer chain; and a sliding seal positioned between said head assembly and said base assembly forms a common chamber enclosing both said reaction well and said nozzles therein.   <IMAGE>
Network PUF - PY2020

The Network PUF (Ntwrk-PUF) is one of the seven files that make up the Marketplace PUF. The Ntwrk-PUF contains issuer-level data identifying provider network URLs. These data either originate from the Network ID template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
2010-2012 NSDUH Substate Estimates of Substance Use and Mental Disorders

This report uses 2010 to 2012 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older by 362 substate regions within the 50 States and the District of Columbia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Compound 526641: 2-O-Acetyl-1,4-Anhydro-3,5-di-O-methyl-L-fucitol

Chemical compound data from PubChem database. IUPAC Name: [4-methoxy-5-(1-methoxyethyl)oxolan-3-yl] acetate. Molecular Formula: C10H18O5. Molecular Weight: 218.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526694: 2,4-di-O-acetyl-1,5-anhydro-3-O-methyl-D-fucitol

Chemical compound data from PubChem database. IUPAC Name: (5-acetyloxy-4-methoxy-6-methyloxan-3-yl) acetate. Molecular Formula: C11H18O6. Molecular Weight: 246.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528470: 1-Undecene, 2,6,10-trimethyl

Chemical compound data from PubChem database. IUPAC Name: 2,6,10-trimethylundec-1-ene. Molecular Formula: C14H28. Molecular Weight: 196.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526406: 7-Bromo,1,3-dichloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 7-bromo-1,3-dichlorodibenzo-p-dioxin. Molecular Formula: C12H5BrCl2O2. Molecular Weight: 331.97. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528450: 1-Hexadecene, 2,7,11,15-tetramethyl

Chemical compound data from PubChem database. IUPAC Name: 2,7,11,15-tetramethylhexadec-1-ene. Molecular Formula: C20H40. Molecular Weight: 280.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525404: 2-Methyl-3,5-dithiahexane

Chemical compound data from PubChem database. IUPAC Name: 2-(methylsulfanylmethylsulfanyl)propane. Molecular Formula: C5H12S2. Molecular Weight: 136.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526973: Lilac alcohol

Chemical compound data from PubChem database. IUPAC Name: 2-(5-ethenyl-5-methyloxolan-2-yl)propan-1-ol. Molecular Formula: C10H18O2. Molecular Weight: 170.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40126-T1: [Translated] 1,5-BENZOTHIAZEPINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND MEDICATIONS.

Novel 1,5-benzothiazepine derivatives of the formula:wherein R<sup>1</sup> is hydrogen or lower alkyl, R<sup>2</sup> is hydrogen, lower alkanoyl or benzyl, R<sup>3</sup> is hydrogen or lower alkyl and either one of R<sup>4</sup> and R<sup>5</sup> is hydrogen and the other is chlorine, or a pharmaceutically acceptable acid addition salt thereof are disclosed. In form of pharmaceutical compositions the said derivative (I) and its salt have a potent platelet aggregation-inhibiting activity.
NNDSS - TABLE 1W. Meningococcal disease, All serogroups to Meningococcal disease, Serogroup B

NNDSS - TABLE 1W. Meningococcal disease, All serogroups to Meningococcal disease, Serogroup B - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
SHIP Children Receiving Blood Lead Screening 2011-2021

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Children Receiving Blood Lead Screening - This indicator reflects the percentage of children (aged 12-35 months) enrolled in Medicaid (90+ days) screened for lead in their blood. Each pediatric Medicaid enrollee should be screened for blood lead during their 12 and 24-month well child visit. Common sources of pediatric lead exposure include dust and paint chips from chipping or peeling lead paint, as well as lead contaminated: soil, toys, water, cosmetics, and folk medicines. <a href ="https://health.maryland.gov/pophealth/Documents/SHIP/SHIP%20Lite%20Data%20Details/Child%20Receiving%20Blood%20Lead%20Screening.pdf" > Link to Data Details </a>
COVID-19 State Profile Report - Nevada

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Patent AT-E401019-T1: [Translated] MOVABLE JOINT SUITABLE FOR A SEATING DEVICE

The present invention relates to a mobile joint ( 1 ) with spring resistance, suitable for a sitting device, comprising a first and a second joint element ( 10, 20 ), which are pivotally connected by a shaft ( 3 ), to allow tilting of the sitting device caused by the displacement of the users weight, comprising a first and a second parallel plate spring ( 18, 19 ) with first and second ends, with an intermediate blocking element ( 11 ), wherein each plate spring ( 18, 19 ) in the first end are connected to the first joint element ( 10 ), and in the second end are glidingly abutting the second joint element ( 20 ), the first and second plate spring ( 18, 19 ) each having an axis of rotation that is displaced in relation to each other and the shaft ( 3 ).
Understanding childhood asthma in focus groups: perspectives from mothers of different ethnic backgrounds

Background
          Diagnosing childhood asthma is dependent upon parental symptom reporting but there are problems in the use of words and terms. The purpose of this study was to describe and compare understandings of childhood 'asthma' by mothers from three different ethnic backgrounds who have no personal experience of diagnosing asthma. A better understanding of parents' perceptions of an illness by clinicians should improve communication and management of the illness.
        
        
          Method
          Sixty-six mothers living in east London describing their ethnic backgrounds as Bangladeshi, white English and black Caribbean were recruited to 9 focus groups. Discussion was semi-structured. Three sessions were conducted with each ethnic group. Mothers were shown a video clip of a boy with audible wheeze and cough and then addressed 6 questions. Sessions were recorded and transcribed verbatim. Responses were compared within and between ethnic groups.
        
        
          Results
          Each session, and ethnic group overall, developed a particular orientation to the discussion. Some mothers described the problem using single signs, while others imitated the sound or made comparisons to other illnesses. Hereditary factors were recognised by some, although all groups were concerned with environmental triggers. Responses about what to do included 'normal illness' strategies, use of health services and calls for complementary treatment. All groups were concerned about using medication every day. Expectations about the quality of life were varied, with recognition that restrictions may be based on parental beliefs about asthma, rather than asthma itself.
        
        
          Conclusion
          Information from these focus groups suggests mothers know a great deal about childhood asthma even though they have no personal experience of it. Knowledge of how mothers from these ethnic backgrounds perceive asthma may facilitate doctor – patient communication with parents of children experiencing breathing difficulties.
Patent AT-E400565-T1: [Translated] NEW BENZOCONDENTED HETEROARYLSULFAMIDE DERIVATIVES SUITABLE AS ANTICONVULSIVE AGENTS

Chemical patent from PubChem database. Patent Number: AT-E400565-T1. Title: Novel Drug Delivery System. Filing Date: 1995-03-27. Inventors: Garcia, Maria, Miller, Thomas. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: C12N, C12P, A61K. This patent covers 17 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
NCHS - Potentially Excess Deaths from the Five Leading Causes of Death

MMWR Surveillance Summary 66 (No. SS-1):1-8 found that nonmetropolitan areas have significant numbers of potentially excess deaths from the five leading causes of death. These figures accompany this report by presenting information on potentially excess deaths in nonmetropolitan and metropolitan areas at the state level. They also add additional years of data and options for selecting different age ranges and benchmarks.

Potentially excess deaths are defined in MMWR Surveillance Summary 66(No. SS-1):1-8 as deaths that exceed the numbers that would be expected if the death rates of states with the lowest rates (benchmarks) occurred across all states. They are calculated by subtracting expected deaths for specific benchmarks from observed deaths.

Not all potentially excess deaths can be prevented; some areas might have characteristics that predispose them to higher rates of death. However, many potentially excess deaths might represent deaths that could be prevented through improved public health programs that support healthier behaviors and neighborhoods or better access to health care services.

Mortality data for U.S. residents come from the National Vital Statistics System. Estimates based on fewer than 10 observed deaths are not shown and shaded yellow on the map.

Underlying cause of death is based on the International Classification of Diseases, 10th Revision (ICD-10)

Heart disease (I00-I09, I11, I13, and I20–I51)
Cancer (C00–C97)
Unintentional injury (V01–X59 and Y85–Y86)
Chronic lower respiratory disease (J40–J47)
Stroke (I60–I69)
Locality (nonmetropolitan vs. metropolitan) is based on the Office of Management and Budget’s 2013 county-based classification scheme.

Benchmarks are based on the three states with the lowest age and cause-specific mortality rates.

Potentially excess deaths for each state are calculated by subtracting deaths at the benchmark rates (expected deaths) from observed deaths.

Users can explore three benchmarks:

“2010 Fixed” is a fixed benchmark based on the best performing States in 2010.
“2005 Fixed” is a fixed benchmark based on the best performing States in 2005.
“Floating” is based on the best performing States in each year so change from year to year.
 
SOURCES

CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES 

1. Moy E, Garcia MC, Bastian B, Rossen LM, Ingram DD, Faul M, Massetti GM, Thomas CC, Hong Y, Yoon PW, Iademarco MF. Leading Causes of Death in Nonmetropolitan and Metropolitan Areas – United States, 1999-2014. MMWR Surveillance Summary 2017; 66(No. SS-1):1-8.

2. Garcia MC, Faul M, Massetti G, Thomas CC, Hong Y, Bauer UE, Iademarco MF. Reducing Potentially Excess Deaths from the Five Leading Causes of Death in the Rural United States. MMWR Surveillance Summary 2017; 66(No. SS-2):1–7.
MD COVID-19 - Cases by Gender Distribution

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of positive COVID-19 cases among Maryland residents by gender: Female; Male; Unknown.

<b>Description</b>
The MD COVID-19 - Cases by Gender Distribution data layer is a collection of positive COVID-19 test results that have been reported each day by the local health department via the ESSENCE system.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.